Findling J W, Buggy B P, Gilson I H, Brummitt C F, Bernstein B M, Raff H
Endocrine Research Laboratory, St. Luke's Medical Center, Milwaukee, Wisconsin 53215.
J Clin Endocrinol Metab. 1994 Oct;79(4):1091-6. doi: 10.1210/jcem.79.4.7962279.
Adrenal dysfunction has been reported in patients infected with the human immunodeficiency virus (HIV). To evaluate the prevalence and degree of adrenal dysfunction in HIV-infected patients, we performed a longitudinal study in 53 ambulatory HIV patients. The plasma cortisol, aldosterone, and dehydroepiandrosterone (DHEA) responses to cosyntropin (250 micrograms, i.v.) were evaluated at 6-month intervals for 24 months and compared to those of normal subjects. The basal and peak cortisol responses to cosyntropin were normal in all HIV patients during the study. There was no difference in the mean basal or stimulated cortisol measurements between Center for Disease Control (CDC) class II-III and CDC class IV patients. Although the mean peak aldosterone response to cosyntropin in HIV patients did not differ from that in normal subjects during the study, the aldosterone secretory capacity was significantly less in CDC class IV than CDC class II-III patients at 6- and 18-month intervals. In addition, there was an impaired aldosterone response to cosyntropin in 31-53% of CDC class IV patients and in only 0-26% of CDC class II-III patients. The mean peak DHEA response to cosyntropin in HIV patients was significantly less than that in normal subjects during the entire study. Basal plasma aldosterone, PRA, cortisol, and DHEA levels did not change in 25 HIV patients who were followed for the entire 24-month period. However, plasma ACTH in these 25 patients was significantly increased at 24 months (9.7 +/- 0.9 pmol/L) compared to that at study entry (7.0 +/- 0.7 pmol/L). Of these 25 patients, 8 had plasma ACTH concentrations that exceeded the normal range at 24 months. The subnormal aldosterone and DHEA secretion with normal cortisol production in these HIV patients is similar to the alterations in adrenal function reported in seriously ill patients without HIV infection. Although we found that clinically significant adrenal insufficiency is uncommon, the elevations in plasma ACTH in several patients at the end of our 2-yr study suggest that adrenocortical capacity may become compromised.
据报道,感染人类免疫缺陷病毒(HIV)的患者会出现肾上腺功能障碍。为评估HIV感染患者肾上腺功能障碍的患病率和程度,我们对53名非卧床HIV患者进行了一项纵向研究。在24个月内,每隔6个月评估一次血浆皮质醇、醛固酮和脱氢表雄酮(DHEA)对促肾上腺皮质激素(250微克,静脉注射)的反应,并与正常受试者的反应进行比较。在研究期间,所有HIV患者对促肾上腺皮质激素的基础和峰值皮质醇反应均正常。疾病控制中心(CDC)II - III级患者与IV级患者的平均基础或刺激皮质醇测量值没有差异。虽然在研究期间HIV患者对促肾上腺皮质激素的平均峰值醛固酮反应与正常受试者没有差异,但在第6个月和第18个月时,CDC IV级患者的醛固酮分泌能力明显低于CDC II - III级患者。此外,31% - 53%的CDC IV级患者对促肾上腺皮质激素的醛固酮反应受损,而CDC II - III级患者中只有0% - 26%出现这种情况。在整个研究期间,HIV患者对促肾上腺皮质激素的平均峰值DHEA反应明显低于正常受试者。在整个24个月的随访期间,25名HIV患者的基础血浆醛固酮、肾素活性(PRA)、皮质醇和DHEA水平没有变化。然而,与研究开始时(7.0±0.7皮摩尔/升)相比,这25名患者在24个月时的血浆促肾上腺皮质激素显著升高(9.7±0.9皮摩尔/升)。在这25名患者中,有8名在24个月时血浆促肾上腺皮质激素浓度超过正常范围。这些HIV患者中醛固酮和DHEA分泌低于正常水平而皮质醇产生正常的情况,与未感染HIV的重症患者所报道的肾上腺功能改变相似。虽然我们发现临床上显著的肾上腺功能不全并不常见,但在我们为期2年的研究结束时,几名患者血浆促肾上腺皮质激素的升高表明肾上腺皮质功能可能会受到损害。